Trial Profile
A Phase II Trial Of The JAK-Inhibitor Ruxolitinib (INCB018424) In Combination With Exemestane For Patients With Estrogen Receptor (ER) Positive Advanced Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Mar 2023
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary) ; Exemestane
- Indications Advanced breast cancer
- Focus Adverse reactions
- Acronyms JAKEE
- 15 Apr 2019 Status changed from active, no longer recruiting to completed.
- 23 Sep 2016 Status changed from recruiting to active, no longer recruiting.
- 13 Jan 2016 Planned primary completion date changed from 1 Oct 2015 to 1 Oct 2017 as reported by ClinicalTrials.gov.